Search
NEW YORK (September 17, 2024) – Marshall Dworkin, an experienced litigator, has become counsel in Saul Ewing’s New York office, joining former colleagues James Chou and Peter Zlotnick. Mr. Dworkin is a litigator with substantial experience representing clients in commercial, insurance and...
Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the NJBIZ 2024 Law Power 50 list. This is the sixth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list...
Introduction On June 18, 2024, the Federal Trade Commission (“FTC”) unanimously agreed to submit a comment supporting a recent proposed U.S. Patent and Trademark Office (“PTO”) rule that would mandate the disclosure of all settlement agreements made between parties appearing before the Patent Trial...
A bipartisan group of representatives, led by Representatives Maria Elvira Salazar (R-FL) and Veronica Escobar (D-TX), have introduced an updated version of the Dignity Act (H.R. 3599) to fix what they call the nation’s fractured immigration system. The authors of the bill call it the first serious...
Minnesota has a unique statute that allows minority shareholders in a closely held corporation to initiate an action for a buy-out of their interests. Minn. Stat. § 302A.751, subdivision 2. Under the Minnesota Business Corporation Act, a closely held corporation is a corporation with 35 or fewer...
On Friday, April 19, 2024, the United States Environmental Protection Agency (“EPA”) announced its final rule designating perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act...
In a recent announcement, U.S. Citizenship and Immigration Services (USCIS) revealed pivotal final rule aimed at fortifying the integrity of the H-1B registration process and minimizing the potential for fraud. This comprehensive update includes beneficiary-centric selection, flexible petition start...
January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...
The Department of Homeland Security (DHS) has put forth a Proposed Rule in January 2023 (“Proposed Rule”), suggesting fee increases and other modifications. Under this proposal, the U.S. Citizenship and Immigration Services (USCIS) increase filing costs for many immigration benefit petitioners and...
JTC AND SAUL EWING LLP PRESENT THE 2ND ANNUAL ADVANCED EB-5 INDUSTRY CONFERENCE - November 9, 2023 - Ronnie Fieldstone to Speak at Event This time last year, the EB-5 industry was in upheaval, with much uncertainty after the passage of the EB-5 Reform and Integrity Act of 2022. Now that the dust has...
Cynthia Gomez will be a Panelist at the October 18th CLE Luncheon Hosted by the American Immigration Lawyers Association in Miami, FL. Cynthia will be one of four panelists, along with leaders from the Customs and Border Patrol offices in South Florida. The topic for Cynthia's panel is Department of...
It's Who You Know - Tips for Building Your Community and Brand Moderator: Michael Joyce, Saul Ewing; Panelists: Paul Malanowski, Saul Ewing, Shannon Lombardo, Saul Ewing, and Nathan Platt, Deputy General Counsel at Liberty Tire Recycling As in-house counsel, developing and utilizing your network is...
NEW YORK, NY, (June 27, 2023) – In joining Saul Ewing as a new partner, Peri Berger will represent clients facing complex commercial disputes involving breach of contract, fraud, business ownership and control, intellectual property, trade secrets and other threats related to their operations in...
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...
The much-anticipated Stakeholders’ call took place on April 25th. As expected, there was not a lot of detailed direction provided although it was acknowledged that to the extent questions were not answered USCIS would try to otherwise address the questions at a later point in time. The following...